Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$102.74

-0.84 (-0.81%)

16:02
11/04/19
11/04
16:02
11/04/19
16:02

Neurocrine reports Q3 EPS 56c, consensus 54c

Reports Q3 revenue $222.1M, consensus $211.63M. "We are pleased that a record number of new patients initiated treatment with INGREZZA as healthcare providers continue to recognize and treat the involuntary movements associated with tardive dyskinesia," said Kevin Gorman, Ph.D., CEO of Neurocrine Biosciences. "Our development programs continue to progress including engagement with regulatory agencies on the adult CAH pivotal trial design. We remain focused on providing patients with access to INGREZZA and preparing for the approval of opicapone in the U.S., while investing strategically to position the company as a leading global biopharmaceutical organization."

  • 04

    Nov

NBIX Neurocrine
$102.74

-0.84 (-0.81%)

08/07/19
08/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bilibili (BILI) initiated with a Buy at Goldman Sachs. 2. Waste Connections (WCN) was initiated with an Overweight at JPMorgan, while Waste Management (WM) and Republic Services (RSG) were initiated with a Neutral. 3. Neurocrine (NBIX) initiated with an Outperform at RBC Capital. 4. Brookfield Property (BPY) initiated with an Outperformer at CIBC. 5. Dropbox (DBX) initiated with an Underperform at Bernstein. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/28/19
GSCO
08/28/19
NO CHANGE
Target $110
GSCO
Buy
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
To reflect the slower than expected ramp in sales of Orilissa in endometriosis, Goldman Sachs analyst Paul Choi lowered his Neurocrine Biosciences (NBIX) forecasts of Orilissa royalties. He projects similar 40% market share by 2026 for both Myovant Sciences' (MYOV) relugolix and Orilissa within endometriosis and uterine fibroid patients treated with a GnRH receptor antagonists. However, in the near-term, since Orilissa royalties are a small fraction of Neurocrine's revenue, these changes have little impact on the company's top- and bottom- lines, says Choi. As such, the analyst keeps a Buy rating on Neurocrine Biosciences with a $110 price target.
09/25/19
RBCM
09/25/19
NO CHANGE
RBCM
Outperform
Neurocrine approval in Huntington's could add upside, says RBC Capital
RBC Capital analyst Brian Abrahams noted that a posting to the ClinicalTrials.gov site revealed that Neurocrine Biosciences is studying the use of Ingrezza in the treatment of Huntington's Chorea. He thinks that Ingrezza's strong position in the tardive dyskinesia market could be a boon for the drug in a new indication and predicts that eventual approval in Huntington's could potentially add as much as an added 20% to out-year revenue estimates for the drug. Abrahams keeps an Outperform rating on Neurocrine shares.
10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.

TODAY'S FREE FLY STORIES

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:19
12/13/19
12/13
15:19
12/13/19
15:19
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the week, the Russell…

IWM

iShares Trust Russell 2000 Index Fund

$163.03

-0.92 (-0.56%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

, XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

15:18
12/13/19
12/13
15:18
12/13/19
15:18
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

XLE

Energy Select Sector SPDR

$60.31

-0.55 (-0.90%)

XLB

S&P Select Materials SPDR

$60.50

-0.42 (-0.69%)

XLK

Technology Select Sector SPDR

$89.50

0.61 (0.69%)

XLI

Industrial Select Sector SPDR

$81.67

-0.25 (-0.31%)

XLF

Financial Select Sector

$30.71

-0.11 (-0.36%)

XLU

Utilities SPDR

$63.39

0.53 (0.84%)

SPY

SPDR S&P 500 ETF Trust

$317.32

0.18 (0.06%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/19
12/13
15:17
12/13/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/19
12/13
15:16
12/13/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

, NTNX

Nutanix

$32.95

0.34 (1.04%)

15:15
12/13/19
12/13
15:15
12/13/19
15:15
Periodicals
Dell looking to broaden infrastructure lead on Nutanix, CRN says »

Dell Technologies (DELL)…

DELL

Dell Technologies

$49.35

-0.15 (-0.30%)

NTNX

Nutanix

$32.95

0.34 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 16

    Dec

  • 09

    Jan

  • 27

    Feb

GOOS

Canada Goose

$40.14

-0.005 (-0.01%)

15:14
12/13/19
12/13
15:14
12/13/19
15:14
Periodicals
DA Davidson analyst sees Canada Goose prices falling, NY Post says »

DA Davidson analyst John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$357.87

-1.83 (-0.51%)

15:04
12/13/19
12/13
15:04
12/13/19
15:04
Periodicals
NHTSA to probe December 7 crash of Tesla Model 3, Reuters reports »

The agency will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Mar

LYV

Live Nation

$70.64

1.2 (1.73%)

15:02
12/13/19
12/13
15:02
12/13/19
15:02
Periodicals
DoJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
12/13/19
12/13
15:00
12/13/19
15:00
General news
Treasury Market Summary »

Treasury Market Summary:…

LYV

Live Nation

$70.63

1.19 (1.71%)

14:57
12/13/19
12/13
14:57
12/13/19
14:57
Periodicals
DOJ preparing to take legal action against Live Nation over ticketing, WSJ says »

The Department of Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

, LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

14:55
12/13/19
12/13
14:55
12/13/19
14:55
Hot Stocks
Eagle Pharmaceuticals reports settlement agreement with Eli Lilly on Pemfexy »

Eagle Pharmaceuticals…

EGRX

Eagle Pharmaceuticals

$59.90

0.73 (1.23%)

LLY

Eli Lilly

$121.30

-0.39 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

  • 17

    Dec

  • 30

    Jan

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

, GILD

Gilead

$65.67

-1.97 (-2.91%)

14:52
12/13/19
12/13
14:52
12/13/19
14:52
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$64.01

0.05 (0.08%)

GILD

Gilead

$65.67

-1.97 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

BRFRF

Burford Capital

$0.00

(0.00%)

14:46
12/13/19
12/13
14:46
12/13/19
14:46
Hot Stocks
Muddy Waters' Block says still short Burford Capital »

Muddy Waters' Carson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDE

Andersons

$24.03

-0.35 (-1.44%)

14:37
12/13/19
12/13
14:37
12/13/19
14:37
Hot Stocks
Andersons raises dividend to 17.5c from 17c per share »

The Andersons announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

, MDT

Medtronic

$113.56

1.17 (1.04%)

14:36
12/13/19
12/13
14:36
12/13/19
14:36
Recommendations
TNDM, Medtronic analyst commentary  »

Craig-Hallum reiterates…

TNDM

TNDM

MDT

Medtronic

$113.56

1.17 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

, GILD

Gilead

$65.76

-1.88 (-2.78%)

14:30
12/13/19
12/13
14:30
12/13/19
14:30
Periodicals
Bristol-Myers awarded $585M in damages in patent win over Gilead, Bloomberg says »

Bristol-Myers (BMY) was…

BMY

Bristol-Myers

$64.19

0.23 (0.36%)

GILD

Gilead

$65.76

-1.88 (-2.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
12/13/19
12/13
14:17
12/13/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
12/13/19
12/13
14:16
12/13/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

, IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

14:08
12/13/19
12/13
14:08
12/13/19
14:08
Technical Analysis
On The Fly: ETF fund flow highlights »

For the second week,…

VOO

Vanguard S&P 500 ETF

$291.59

0.33 (0.11%)

IVV

iShares Core S&P 500

$319.25

0.36 (0.11%)

XLE

Energy Select Sector SPDR

$60.65

-0.21 (-0.35%)

XLF

Financial Select Sector

$30.74

-0.08 (-0.26%)

QQQ

Invesco QQQ Trust

$207.32

0.76 (0.37%)

SPY

SPDR S&P 500 ETF Trust

$317.43

0.29 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:01
12/13/19
12/13
14:01
12/13/19
14:01
Hot Stocks
Tandem Diabetes up 5% upon resumption following FDA approval news »

After resuming trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNDM

TNDM

14:00
12/13/19
12/13
14:00
12/13/19
14:00
Hot Stocks
Breaking Hot Stocks news story on TNDM »

Tandem Diabetes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$218.24

-2.19 (-0.99%)

13:57
12/13/19
12/13
13:57
12/13/19
13:57
Hot Stocks
Vertex expands long-term CF medicines reimbursement agreement with Ireland »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

13:55
12/13/19
12/13
13:55
12/13/19
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

SNE

Sony

$67.65

0.34 (0.51%)

, T

AT&T

$38.15

-0.2 (-0.52%)

13:52
12/13/19
12/13
13:52
12/13/19
13:52
On The Fly
Box Office Battle: 'Jumanji' sequel expected to dethrone 'Frozen II' »

Welcome to "Box Office…

SNE

Sony

$67.65

0.34 (0.51%)

T

AT&T

$38.15

-0.2 (-0.52%)

CMCSA

Comcast

$43.59

0.57 (1.33%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$9.81

-0.18 (-1.80%)

LGF.B

Lionsgate

$9.15

-0.2 (-2.14%)

DIS

Disney

$147.58

1.61 (1.10%)

FOX

Fox Corp.

$36.01

0.05 (0.14%)

FOXA

Fox Corp.

$36.90

0.04 (0.11%)

VIAC

ViacomCBS

$38.51

0.72 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 29

    Jan

T

AT&T

$38.20

-0.15 (-0.39%)

13:45
12/13/19
12/13
13:45
12/13/19
13:45
Hot Stocks
AT&T 'well ahead' of 2019 deleveraging goals »

AT&T has supported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.